Table 1 Subgroup analysis: number of events for local recurrence and deaths and point estimates for local recurrence-free survival are given for 5 years when the follow-up is complete, as per protocol.

From: New clinical and biological insights from the international TARGIT-A randomised trial of targeted intraoperative radiotherapy during lumpectomy for breast cancer

    TARGIT-IORT EBRT TARGIT-IORT EBRT Long-term local control TARGIT-IORT vs EBRT
Subgroup Category No. of cases No. of cases LR Deaths No. of cases LR Deaths Alive without local recurrence Alive without local recurrence Hazard ratio 95% confidence interval of hazard ratio
Tumour size <=10 mm 739 369 10 8 370 2 10 94.9% 96.7% 1.35 0.86–2.10
  11–20 mm 1128 571 11 16 557 5 25 95.5% 94.6% 0.99 0.71–1.37
  >20 mm 366 176 2 18 190 3 20 88.5% 88.2% 1.22 0.80–1.80
Tumour grade Grade 1 or 2 1797 914 17 25 914 7 39 94.9% 96.7% 1.08 0.83–1.40
  Grade 3 443 226 7 17 217 4 17 90.1% 91.1% 1.26 0.82–1.94
ER status ER+  2035 1005 15 35 1030 9 46 94.9% 94.7% 1.12 0.87–1.42
  ER− 207 114 8 6 105 2 10 89.2% 87.7% 0.95 0.55–1.65
PgR status PgR+ 1816 895 13 29 921 9 40 95.1% 94.7% 1.09 0.84–1.41
  PgR− 413 220 10 12 193 2 16 90.7% 90.9% 1.08 0.69–1.70
HER2 status HER2− 1845 920 19 35 925 8 39 94.2% 95.0% 1.12 0.87–1.44
  HER2+  320 156 3 6 164 3 16 94.0% 88.7% 1.36 0.81–2.27
Lymph node status LN− 1765 872 20 27 893 9 42 94.4% 94.4% 1.14 0.88–1.46
  LN+  488 254 4 15 234 2 14 93.0% 93.2% 1.07 0.68–1.70
Overall All patients 2298 1140 24 42 1158 11 56 94.2% 94.2% 1.13 0.91–1.41
  1. LR local recurrence.
  2. The hazard ratio for local recurrence-free survival is given for the whole follow-up period and shows that in every subgroup, there was no significant difference in local control (i.e., the probability remaining local recurrence-free) between TARGIT-IORT and EBRT, and 95% CI of the hazard ratio for local recurrence-free survival crossed 1.0, as represented in Fig. 1.
  3. Patients in whom the specific pathological detail was not known were, —for local recurrence: one in each arm for tumour size, in TARGIT-IORT arm 1 ER/PgR status, 2 HER status and, —for death: one in EBRT arm for tumour size, one in TARGIT-IORT arm for ER/PgR/HER2 status.